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ABSTRACT 
Autoimmune and inflammatory disorders of the central nervous system can result in significant morbidity and mortality. 
Through the recognition of syndromes using diagnostic biomarkers, the clinician is now able to use immune suppressive 
therapies to improve outcomes. However, the therapeutic decision-making process is complex. The clinician has to balance 
the risk of disease, with the risk of treatment side effects. To achieve this balance, it is important to understand the natural 
history of disease, the risk of residual disability, the risk of relapse, and risk of a fatal outcome. It is also important to have 
some understanding of the pathological processes, as some of the entities have more reversible processes, whereas others 
have destructive processes. This review will assess the dynamic nature of this decision-making process, and compare some 
of the more severe diseases such as neuromyelitis optica, anti-N-methyl-D-aspartate receptor encephalitis and opsoclonus 
myoclonus ataxia syndrome, with disorders with more favourable outcomes such as Sydenham chorea and post-infectious 
cerebellar ataxia. 
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INTRODUCTION
Inflammation of the central nervous system is potential-
ly life threatening and disabling. Through the discovery of 
biomarkers to define inflammation and diagnose specific 
diseases [1], clinicians are more willing to use immune sup-
pressive agents to reduce inflammation in order to improve 
outcomes. However, immune suppressive therapies have 
side effects and it is therefore important to appreciate the 
risk of disability or death of the disease, and balance this 
with the risk of adverse events. This paper attempts to over-
view the clinical decision-making involved in this process, 
and is intended as a discussion document, rather than a 
guideline or systematic review.
OVERVIEW OF THE DISEASE SPECTRUM
Table 1 summarises the main inflammatory and autoimmune 
disorders of the central nervous system (CNS) that affect 
children. Multiple sclerosis is not discussed here, because 
it is dealt with in detail elsewhere, and the therapeutic path-
ways are different. The table does not constitute a system-
atic review of the literature, but instead samples the larger 
cohorts that report data on the severity of disease, risk of 
relapse and outcomes; nor is it exhaustive and does not 
consider rare or poorly defined disorders such as suspected 
autoimmune encephalopathy syndromes. The disorders are 
generally categorised into demyelination syndromes, auto-
immune encephalitis, autoimmune movement and cerebel-
lar syndromes, cerebral vasculitis and CNS complications 
of systemic autoimmune disease such as neuropsychiatric 
systemic lupus erythematosus (SLE). 
UNDERSTANDING SEVERITY 
OF ACUTE DISEASE
In the past, CNS inflammation such as acute disseminated 
encephalomyelitis (ADEM) and Sydenham chorea was of-
ten observed and treated with symptomatic therapies only, 
as patients tended to improve. However it is now generally 
accepted that brain inflammation of any type is potentially 
damaging, and can result in permanent alteration of the CNS 
[14,15]. The severity of the acute disease is variable; ADEM 
and anti-N-methyl-D-aspartate receptor (anti-NMDAR) en-
cephalitis often run a more severe acute course, often re-
quiring intensive care (43 and 75% respectively) [2,6]. Being 
admitted to intensive care presents significant risk to the 
patient and is associated with poor outcomes [6], and try-
ing to shorten the intensive care admission is important. By 
contrast, in many of these other conditions intensive care 
support is unusual. 
JICNA Journal of the International Child Neurology Association
A peer reviewed open access e-journal in Child Neurology
®
SCIENTIFIC REVIEW
OPEN 
ACCESS
Dale et al. JICNA 2016, 16:112
2
Table 1. Understanding risk of relapse and risk of permanent disability (i.e. natural history)
We use large cohorts with adequately described data, children only. Cohorts are contemporary ‘treated’ cohorts, rather than 
‘natural history’ cohorts. Unfortunately different publications use different definitions of ‘favourable outcome’- in general this 
refers to normal outcome, but sometimes includes better outcomes with mild problems (modified Rankin score, mRS 0-2). 
The outcomes and deaths are those directly attributed to CNS disease, as opposed to other-organ disease effects (such as 
in SLE and Rheumatic fever). 
Disease category Disease Relapse %
Favourable 
outcome %
Death
2nd line 
therapies 
used
Ref
Acute demyelinating 
syndromes
Acute disseminated 
encephalomyelitis (n=84)
10% 89% ^ <2% No [2]
Transverse myelitis (n=95) 17% 70%## <2% Occasional [3]
Optic neuritis (n=36) 36% 80% <1% No [4]
Neuromyelitis optica (n=20) 90% <50% ** <5% Yes [5]
Autoimmune encephalitis
Anti-NMDAR encephalitis  
(n=211 children)
12% 58%  3% Yes * [6]
Autoimmune movement and 
cerebellar syndromes
Opsoclonus myoclonus 
ataxia syndrome (n=105)
52% 25% <2% Yes [7]
Sydenham chorea (n=24) 42% 90%^^ <1% No [8]
Cerebellitis (n=11) <10% <50% ~5-10% No # [9]
Post-infectious cerebellar 
ataxia (n=73)
<5% 89% <1% No [10]
Cerebral vasculitis
Primary angiitis of CNS 
(n=19)
42% 70% <5% Yes [11]
CNS complications of 
systemic autoimmune disease
Neuropsychiatric SLE 
(n=100)
20% 75% 3% Yes [12]
* Child only data, apart from relapse rate (child and adult)
** at follow-up after relapsing course. Monophasic disease can have significantly better outcomes. 
^ Expanded disability status score, EDSS 0-2
^^ Persistent mild chorea, and persistent psychiatric symptoms are common, although severe problems are uncommon
# Cerebellitis is a severe syndrome with potential risk of death (due to herniation) and disability, however the disease is rare and poorly understood, 
and so 2nd line therapy is not promoted (although could be justified)
## The largest cohort of transverse myelitis reported better outcomes than previous cohorts which reported <50% favourable outcomes [13]. 
UNDERSTANDING RISK OF 
PERMANENT DISABILITY
A further important consideration is the risk of permanent 
disability. This risk is partly related to the initial episode, but 
also related to the accumulative damage associated with 
disease relapses. For example, relapses increase disability 
in neuromyelitis optica (NMO), although patients can be left 
with permanent disability after a single event, partly related 
to the severity of the pathology (discussed later). As present-
ed in Table 1, the risk of permanent disability varies by dis-
ease. However, the information provided in Table 1 does not 
adequately address the complexity of this issue. For exam-
ple, in Sydenham chorea, historically considered a ‘benign’ 
disorder requiring no treatment, a significant proportion of 
patients are left with permanent neuropsychiatric alteration 
or residual mild chorea - not enough to represent ‘major 
disability’, but potentially life altering [15,16]. Likewise, the 
residual cognitive deficits after ADEM are probably under-re-
ported and under-appreciated [17-19]. However, for some 
of these disorders, such as NMO, anti-NMDAR encephali-
tis and cerebral vasculitis, the risk of permanent disability 
is significant, and therefore it is easier to rationalize more 
potent immune suppression to try to improve outcomes [6]. 
There is now reasonable retrospective evidence in NMO, 
anti-NMDAR encephalitis, opsoclonus myoclonus ataxia 
syndrome (OMAS) and cerebral vasculitis, that more potent 
immune suppression and use of second line therapies (as 
discussed later) improve the course of the acute disease, re-
duce relapse and improve long-term outcomes [6,11,20,21]. 
However, there are no randomized controlled trials in these 
rare disorders to provide a strong evidence for this approach 
at this time. 
UNDERSTANDING SPEED OF RECOVERY 
AND PERSISTENT CNS INFLAMMATION
The ability to determine when a patient is not following the 
expected speed of improvement is very challenging, and of-
ten requires previous experience with these conditions. The 
different disorders require different expectations, which will 
influence therapeutic decision-making. For example in acute 
ADEM and transverse myelitis, there is typically a rapid im-
provement during the first days after starting intravenous 
methylprednisolone, and poor improvement after 5-7 days 
may alert the clinician that the patient is not following the 
expected trajectory, and escalation of therapy should be 
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considered. By contrast, patients with anti-NMDAR enceph-
alitis (particularly when the disease is diagnosed later) will 
not respond rapidly to immune suppression, and it is rec-
ommended to wait 10-14 days after first line therapy before 
escalating [6]. However this decision is further complicated 
by the severity of disease. For example, a patient with an-
ti-NMDAR encephalitis who has the ‘full syndrome’ with re-
spiratory and autonomic dysfunction on intensive care is at 
high risk, and so escalation to second line therapy should be 
considered early, whereas milder patients on the ward may 
be observed for a longer. However, there is a general theme 
emerging for autoimmune CNS disorders, that early immune 
therapy improves outcomes and thus should not be delayed, 
particularly in very symptomatic or critically ill patients [21]. 
Furthermore, patients with anti-NMDAR encephalitis often 
take a long time to recover, require prolonged hospital ad-
missions, and improvements continue for up to 2 years [6]. 
Defining when a patient is not improving adequately is chal-
lenging, and the autoantibody biomarkers should generally 
not be used in this decision making process, as antibodies 
can remain positive in serum and cerebrospinal fluid (CSF) 
for years, and titres are not very reliable in monitoring of dis-
ease (although tend to reduce with improvements, and in-
crease with relapses). Instead, other markers of CNS inflam-
mation are probably more useful such as CSF neopterin [22], 
although there is a paucity of CSF and brain inflammatory 
biomarkers available in clinical practice, and there are few 
biomarkers that have been used longitudinally to determine 
disease progress. A recent study showed that the chemok-
ine CXCL13 is elevated in CSF in anti-NMDAR encephalitis, 
and is more elevated in patients who have a poor outcome or 
relapse [23]. Biomarkers that can help in disease monitoring, 
in addition to clinical monitoring are required, as determining 
when a patient is failing to improve is a major management 
challenge to clinicians. 
UNDERSTANDING RISK OF RELAPSE
A crucial factor in deciding longer term maintenance immu-
notherapy is the inherent risk of relapse. Aquaporin-4 (AQP4) 
antibody positive NMO is typically relapsing (table 1) [5]. It is 
accepted that relapse prevention reduces disability in NMO, 
and therefore reducing relapses should be a primary con-
sideration, and it would be appropriate to plan maintenance 
immune suppressant regimen even at the first acute event. 
By contrast, many of the other conditions are predominantly 
monophasic (Table 1), where longer term immunotherapy is 
often considered only at relapse. It should be noted that the 
risk of relapse in many of these disorders has changed com-
pared to earlier descriptions. For example, for anti-NMDAR 
encephalitis, the relapse rate was ~25% initially, but with 
increasing immune suppression in the acute phase, the re-
lapse rate has reduced to ~12% [6]. A similar phenomenon 
has occurred in OMAS [20,24]. There is emerging evidence 
that the relapse risk is influenced by early and perhaps more 
systematic immune suppression in the acute presentation 
[6,25].
UNDERSTANDING NEUROPATHOLOGY 
AND REVERSIBILITY OF DISEASE
Table 2 attempts to summarise the pathological processes 
occurring in these disorders, which are variable. It is import-
ant to appreciate this variability, as these disorders are not 
the same, for example it is reasonable to undertake ‘watch-
ful waiting’ in Sydenham chorea or post-infectious cerebel-
lar ataxia, whereas in more severe indications such as NMO 
and cerebral vasculitis, it is reasonable to escalate quickly to 
second line therapies (or even use second line therapies at 
initiation of therapy). 
The pathology of many CNS autoimmune and inflamma-
tory disorders is often inferred from limited cases that are 
often poorly clinically defined, or are biased towards atypical 
or severe cases (such as post mortem cases). Additionally 
cases studied usually reflect chronic rather that acute patho-
biology. In many of the disorders, a perivascular lymphocytic 
infiltration is common, and not very specific for any particu-
lar entity. A study of autoimmune encephalitis pathology in 
adults noted significant variability in pathology [34]. For ex-
ample in anti-NMDAR encephalitis, there is a lymphocytic in-
filtration predominantly of plasma cells, and in vitro [32] and 
animal studies [33] consistently demonstrate that the effect 
of antibody on neurons and disease symptomatology is re-
versible, as is often observed in patients,  although this may 
take up to 2 years [6]. By contrast, NMO is a destructive pa-
thology, with cavitation and astrocyte loss, complement me-
diated cytotoxicity, and secondary demyelination [27]. NMO 
pathology involves T-lymphocytes, neutrophils, eosinophils, 
as well as autoantibody-mediated pathology [27]. Therefore 
more potent immune therapy is justified to prevent irrevers-
ible astrocyte loss and its downstream effects on neuropa-
thology. Likewise, cerebral vasculitis often has associated 
cell death with secondary hypoxic ischaemic brain injury, 
which is irreversible [32]. Neuropsychiatric SLE is complex 
with many clinical syndromes, and multiple complex patho-
physiological processes (immunological, vascular, or both), 
and may require immune suppressive and anti-thrombotic 
therapies [35].  It is important to understand the pathological 
process of the disease we are treating, as more potent im-
mune suppression can be justified, when more destructive 
and irreversible pathobiology has been established.  
UNDERSTANDING INTRATHECAL 
AUTOIMMUNITY AND THE ROLE 
OF THE BLOOD BRAIN BARRIER
A key conundrum in these disorders is if the inflammatory 
process is ‘established’ in the CNS or is driven systemically. 
In anti-NMDAR encephalitis, there is clear evidence of an ac-
tive intrathecal inflammation with CSF pleocytosis, intrathe-
cal oligoclonal bands, and intrathecal production of NMDAR 
antibodies. By contrast, in other disorders, such as ADEM 
associated with anti-MOG antibodies, there is typically not 
intrathecal production of autoantibody, although the timing 
of testing is likely to influence some of these findings [36].  
Knowing if neuroinflammation is predominantly driven 
centrally or peripherally may influence how we choose or 
direct therapy.   Plasma exchange (PLEX) will remove circu-
lating antibody, lymphocytes and other molecules, and will 
subsequently result in less circulating immune molecules en-
tering the CNS, but PLEX will not necessarily reduce estab-
lished intrathecal inflammation (when present), so it should 
probably not be used in isolation in anti-NMDAR encephali-
tis, but instead should be used in conjunction with cortico-
steroids or other agents that have access to the CNS. 
A further poorly investigated consideration is the role of 
the blood brain barrier (BBB) in these disorders. It is often 
assumed and cited that the BBB is altered or disrupted in 
inflammatory CNS syndromes (although not necessari-
ly proven), extrapolated from studies in multiple sclerosis. 
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Whilst reducing BBB disruption, such as treating infection 
and trying to reduce the BBB permeability can be, in theory, 
of value [37], this strategy may  significantly reduce the CSF 
penetration of  immune therapy.
THERAPIES AND MECHANISMS
Acute therapy
Figure 1 demonstrates the generally accepted pathway for 
treating inflammatory and autoimmune CNS disorders. 
First line acute therapies are often corticosteroids, intra-
venous immunoglobulin (IVIG) and PLEX, used sequential-
ly or in combination. Despite the paucity of good reported 
evidence of efficacy, IVIG is often used by many paediatric 
neurology centres and is generally considered to be useful. 
However, it is expensive and availability may often be re-
stricted. PLEX is technically difficult, and is less accessible 
as a result of this, particularly in the very young child. There 
is a paucity of literature regarding the safety and tolerability 
of PLEX in young children with autoimmune CNS disease. 
In most clinical situations steroids are initiated first fol-
lowed by IVIG, and following that PLEX.  IVIG may be used 
first instead of steroids if there remains some uncertainty of 
acute invasive infections. In situations, such as a child with 
severe CNS inflammatory disorder like anti-NMDAR enceph-
alitis requiring intensive care support, where PLEX is consid-
ered likely to be necessary, it would be pragmatic that IVIG 
be considered post PLEX, avoiding the inadvertent removal 
of IVIG by PLEX and therefore ameliorating its effect.   The 
mechanisms of action, the speed of action, and the side ef-
fects of the first and second line therapies are presented in 
brief in table 3. 
 When CNS inflammation is refractory to 1st line therapy, 
second line therapy can be considered such as rituximab 
and cyclophosphamide (separately or together), but these 
should be reserved for diseases with higher risk such as 
anti-NMDAR encephalitis, NMO, OMAS, cerebral vasculitis 
and neuropsychiatric SLE [21]. Steroid sparing agents such 
as azathioprine and mycophenolate mofetil (MMF) take 3-6 
months to be effective so are not useful if a more immediate 
effect is required. On occasions neurosurgical intervention is 
required in the treatment of malignant brain oedema as seen 
in cerebellitis and less commonly in ADEM [9]. 
Maintenance therapy
Once the acute therapy is complete, if there is a risk of re-
lapse that is considered significant (as discussed above), 
then chronic immune suppression can be considered. Aza-
thioprine and MMF are most commonly used in this setting, 
but due to the latency of their effect, steroid cover (or other 
immune therapy) will be needed until the drugs are effective. 
An alternative approach is monthly IVIG but this is expensive 
and may be less effective in some disorders such as OMAS 
[20]. An alternative approach to chronic immune suppression 
is re-dosing rituximab. Rituximab usually produces 6 months 
of demonstrable B cell depletion, although can last >12 
months in 10% of treated patients [21]. In disorders when 
the risk of relapse is high (in frequency and severity), such as 
NMO, re-dosing of rituximab can be considered. If re-dos-
ing of rituximab is planned, it is important to appreciate the 
Table 2. Pathological findings in the autoimmune and inflammatory CNS disorders.  
The symbol (-) denotes there is inadequate literature.
Disease category Disease Summary of brain pathology Ref
Inflammatory 
demyelination
Acute disseminated 
encephalomyelitis
Perivenular lymphocytic infiltration (predominantly T cells) with 
only minor demyelination.
[26]
Transverse myelitis -
Optic neuritis -
Neuromyelitis optica 
(AQP4 ab)
Astrocytopathy with secondary demyelination. 
Perivascular inflammation with adaptive (B and T cells), and 
innate (neutrophils, eosinophil) activation.
Immunoglobulin and complement deposition.
Destructive and cavitating pathology.
[27]
Autoimmune 
encephalitis
Anti-NMDAR  
encephalitis
Perivascular lymphocytic infiltration (predominant plasma cell), 
absence of complement.
[28]
Autoimmune 
movement 
and cerebellar 
syndromes
Opsoclonus myoclonus 
ataxia syndrome
Sometimes little pathological abnormalities. Periaqueductal 
inflammatory cells.
[29]
Sydenham chorea Perivenular inflammation, predominantly involving striatum. [30]
Cerebellitis
Cerebellar leptomeningeal and parenchymal
lymphocyte (T and B) and eosinophil infiltration.
[31]
Post-infectious  
cerebellar ataxia
-
Cerebral vasculitis  Primary angiitis of CNS
Inflammatory infiltrate (predominantly lymphocytes) located in 
intramural
blood vessels. Secondary ischaemia.
[32]
CNS complications 
of systemic 
autoimmune disease
Neuropsychiatric SLE
Variable with either dominant thromboembolic, ischaemic or 
haemorrhagic features.
[33]
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IVMP 
30 mg/kg x 3-5 days 
(max 1 g/day)
First clinical event 
of paediatric 
autoimmune and/or 
inammatory 
disorder of the CNS
Relapsing disease
First-line 
immune therapy
Second-line 
immune therapy
PE 
5-7 courses 
on alternate days
IVIG
 2 g/kg 
in 2 or 5 days
IVIG
 0.5-2 g/kg 
monthly
OP 
taper
CYC
Chronic immune 
therapy
MMF
or
AZA
or
RTX
or
or
RTX
No response to rst-line 
immune therapy and 
severe disease
Legend
AZA: Azathioprine
CYC: Cyclophosphamide
IVIG: intravenous 
Immunoglobulin
IVMP: intravenous 
Methylprednisolone
MMF: Mofetil 
mycophenotale
RTX: Rituximab
Good 
response to 
rst-line 
immune 
therapy
Alternative 
immunosupression 
Reconsideration 
of diagnosis
Clinical neurological, 
neuropsychological 
and 
neuroradiological 
monitoring
Clinical neurological, 
neuropsychological 
and 
neuroradiological 
monitoring
No response and 
severe disease
Good 
response to 
second-line 
immune 
therapy
High dose 
pulsed steroids
20 mg/m2 x 3 days 
monthly
Figure 1. Trial of first line therapy in confirmed or suspected autoimmune CNS disease. If the patient fails to respond to first 
line therapy, and the disease has significant risk of morbidity or mortality, then second line therapies can be considered. If 
the disease has a relapsing course, or has a high risk of relapse, chronic immune suppression can be considered. 
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Table 3. First and second line drugs used in the treatment of autoimmune and inflammatory CNS  
disorders-mechanism of action, speed of action and common or concerning side effects
Drug
Mechanism  
of action
Expected 
time for drug 
effectiveness
Concerning side effects
1ST LINE IMMUNOTHERAPEUTIC AGENTS
Corticosteroid
Broad anti-inflammatory 
properties, reduce 
swelling and oedema, 
reduce permeability of 
BBB.
Hours/days
Lots of transient side effects: hypertension, 
glycosuria, CNS effects, catabolic effects.
Long term effects: Bone mineralisation, skin 
thinning, infection, cataract, growth suppression, 
cushingoid habitus, metabolic problems.
Intravenous 
immunoglobulin
Multiple immune 
mechanisms involving 
antibody, cytokines, 
cellular.
Hours/days Expensive, allergy, risk of viral transmission.
Plasma exchange
Plasma filtration, remove 
antibody and cytokines.
Hours
Invasive, haemodynamic alteration, large vessel 
access required, infection.
2ND LINE OR MAINTENANCE IMMUNOTHERAPEUTIC AGENTS
Steroid sparer 
(azathioprine, 
mycophenolate mofetil)
Broad cellular immune 
suppressant.
~3 months
Liver dysfunction, increased risk of infection, 
increased cancer risk (small), expensive (MMF).
Rituximab
B cell depleter, 
secondary effects on T 
cells.
1-4 weeks
Infusion side effects common but not serious, 
~1:40 chance of severe serious infection, 
expensive.
Cyclophosphamide
Broad cellular immune 
suppressant.
Days Cystitis, renal toxicity, infection, cancer, infertility.
BBB: blood-brain barrier
timing of B cell repopulation using frequent B cell monitoring 
to prevent the patient relapsing during B cell repopulation 
[38]. Alternatively rituximab can be re-dosed regularly (for 
example every 6 months) although this may in theory result 
in increased side effects [43]. 
UNDERSTANDING RISK OF TREATMENT
It is very important to consider the risk of treatment, as out-
lined in brief in table 3. The majority of these treatment side 
effects are clearly outlined in respective national therapeutic 
formularies, such as the British National Formulary in Chil-
dren (BNFC), where the majority of data is assimilated/de-
rived from the summary of product characteristics (SmPC). 
However, children may be resistant to some of these side 
effects, but vulnerable to others [39]. Furthermore, predicting 
more severe adverse effects remains challenging, as is the 
knowledge of the precise incidence of adverse events. Poly-
morphisms of the thiopurine S-methyltransferase (TPMT) 
gene that determine the metabolism of thiopurines such as 
azathioprine has an established role in screening for patients 
at risk of adverse effects [40]. However, application of this 
for other immune therapeutic agents remains unestablished, 
nor is the role of such pharmacogenetic stratification in op-
timizing treatment [41]. Sick children on intensive care are 
at risk of infection, and immune suppression with multiple 
agents presents significant potential risk [21]. For example, a 
serious infectious side effect that was attributed to immune 
suppression was described in 4 of 144 children receiving 
rituximab for severe inflammatory CNS disorders [21]. Like-
wise, cyclophosphamide brings concerns about malignan-
cy and infertility, as well as infection, although most safety 
data is derived from adult trials [42]. And azathioprine and 
MMF brings risks of infection and a slight increase in risk of 
malignancy. These side effects should be considered during 
the decision-making process, and for this reason, these 
more potent immune suppressants should be reserved for 
more significant diseases that carry inherent risk of disability 
or death. Some of these therapies are not available in re-
source-poor countries. However, many of these conditions 
are responsive to steroids, and can be used in regimens 
to attempt to minimize accumulative side effects (such as 
monthly pulse regimens). Clinicians should use the cortico-
steroid they are most familiar with- there is little data to sug-
gest any particular corticosteroid is superior in this context. 
COUNSELING AND INFORMING 
THE FAMILIES
Families and patients need to be informed about the relative 
risks of therapy, but this needs to be presented in a way that 
helps the family understand that the risks of not giving the 
drug may result in permanent neurological disability. Often 
this is conducted with extrapolated data and is hugely influ-
enced by clinician familiarity with specific agents and/or ex-
perience of adverse events. This counseling is complex, and 
unfortunately can result in families and clinicians becoming 
‘risk averse’ or ‘therapeutically incapacitated’. A confident 
but honest approach is probably most likely to succeed. 
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SUMMARY
Figure 2 illustrates the complex decision-making process, 
trying to weigh up the risk of the disease with the risk of 
the therapy. We are currently in a transitional phase in our 
understanding of these newer disorders. Biomarkers have 
recently informed us about diseases that are treatable. We 
are starting to understand that immune suppressive thera-
pies improve outcomes, reduce relapses and reduce disabil-
ity. However, the therapies are currently hugely empirical and 
based on a generic rather than a disease specific strategy. 
Furthermore, we lack directed therapies that could be more 
effective and better tolerated. There is a significant shortage 
of randomized controlled trials in these disorders, and the 
evidence base is only provided by retrospective cohort data 
and personal opinion that may be biased by experience. Col-
laborative international endeavors are imperative to provide 
progress. 
Figure 2. The complexity of therapeutic decision-making: Balancing the risk of disease with risk of drug side effects. 
The figure demonstrates some of the variables involved in therapeutic decision-making.
Acknowledgements
RCD has support from University of Sydney, the National Health and 
Medical Research Council, and the Petre Foundation.
Competing interests
None
Author contributions
First draft by RCD, subsequent discussions, editing and re-writing 
by all authors. 
This is an Open Access article distributed under the terms of the Cre-
ative Commons Attribution License (http://creativecommons.org/
licenses/by/4.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly 
credited. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the 
data made available in this article, unless otherwise stated.
FACTORS FAVOURING 
FURTHER TREATMENT
Severity of acute condition
Early in disease course
Risk of permanent disability
Reversible disease
Relapse risk
Low side eect prole of treatment
FACTORS FAVOURING OBSERVATION 
OR NO FURTHER TREATMENT
Mild symptoms or good improvement
Late diagnosis
Good outcome
Contribution of immune system unclear
Monophasic illness
Short and long term side eects of treatment
TREATMENT CLOSE SURVEILLANCE WITH 
NO TREATMENT
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